Berge disputes the idea that Americans must travel overseas for ordinary regenerative treatments. He says overseas clinics remain relevant for riskier or more experimental cases that US doctors avoid, including some spinal-cord and brain-function work, while more routine uses are available domestically.

Berge distinguishes niche experimental cases from routine applications
He says regulatory and malpractice risk deter some US doctors
Some doctors maintain both US practices and overseas clinics
He attributes part of general medical tourism demand to overseas marketing

“the only reason you need to go to Panama or overseas to get stem cells would be if you're trying to do something. Like I…”
Seth Berge · 29:00

“there's still a large medical tourism industry for stem cells simply because of of intentional misdirection.”
Seth Berge · 29:30

#medical tourism#regulation#stem cells

Hot Take· 1

Hot Take26:30

Berge Predicts Labs Will Grow Replacement Organs

Looking ahead, Berge speculates that laboratories will eventually use a person's own stem cells to recreate entire organs. He frames replacement hearts grown to order as part of the future of stem-cell therapy, not a current capability.

The claim is explicitly a prediction about the future
Berge imagines using a patient's own stem cells
He expects laboratories to grow complete replacement organs

“There's probably in the not too distant future, they're going to be able to use stem cells to like recreate entire organs”
Seth Berge · 26:30

“Give us a month and the lab will grow you a new one. That's that's honestly the future of of stem cell therapy”
Seth Berge · 27:00

#future medicine#organ regeneration#stem cells

Explainer· 3

Explainer20:00

Stem Cells as Workers, Exosomes as Blueprints

Berge uses a house-building analogy to explain the relationship between stem cells and exosomes. He characterises stem cells as workers doing the repair work and exosomes as messages or blueprints directing those workers.

Berge says stem cells naturally secrete exosomes
He compares stem cells to workers on a building site
He compares exosomes to instructions or a blueprint
His company combines stem cells and exosomes in some products

“the stem cells are like the workers. They're going to be doing the work. The exoomes are going to be sending the messages to the…”
Seth Berge · 20:30

“maybe it's like the exoomes are like the blueprint.”
Seth Berge · 20:30

#stem cells#exosomes#biologics

Explainer30:00

Berge's Case for Uncultured Stem Cells

Berge says US rules require products to be minimally manipulated and prohibit culturing one cell into many. He argues that each division reduces a cell's original character and contrasts large overseas counts with the uncultured cells used in his company's treatment.

Berge says US products must be minimally manipulated
He says cells can be cultured and expanded overseas
He argues expanded cells lose some original character with each iteration
He describes the cells used in Joe's procedure as original and uncultured

“We are not allowed to take one single stem cell and divide it or culture it and expand it.”
Seth Berge · 30:30

“that's 80 million original undifferentiated uncultured cells.”
Seth Berge · 31:00

#cell culture#stem cells#product quality

Explainer33:00

Why Med Spas Are Using Wharton's Jelly

Berge says cosmetic and aesthetic use of stem cells and exosomes has grown rapidly. He describes Wharton's jelly as material from the umbilical cord containing stem cells, collagen, hyaluronic acid, growth factors, cytokines, and naturally occurring exosomes, and recounts his wife's under-eye treatments.

Berge says med spas use exosomes and stem cells with microneedling
He identifies Wharton's jelly as part of the umbilical cord
He says his wife received both exosome and stem-cell treatments
He reports volume lift after three under-eye rounds

“Cosmetic and aesthetics the last few years that's taken off like crazy.”
Seth Berge · 33:00

“the specific part of the umbilical cord called the Wharton's jelly is the richest source in all of Earth for stem cells for collagens type…”
Seth Berge · 34:30

#whartons jelly#aesthetics#med spas#exosomes

Story· 2

Story02:00

How a Serial Entrepreneur Fell Into Regenerative Therapy

Seth Berge says he first saw stem-cell therapy as a business opportunity rather than a health mission. A former partner brought the idea back from a marketing conference, and Berge later found the work more personally rewarding than his previous businesses.

Berge entered the category about eight and a half years earlier
His earlier businesses included financial planning and home improvement
He says seeing changes in customers' lives made the new field meaningful

“I first looked at it from the business opportunity not even necessarily the health and wellness space”
Seth Berge · 03:00

“this is actually fun and rewarding, you know, getting to see lives change”
Seth Berge · 03:30

#entrepreneurship#career story#regenerative medicine

Story24:30

A 2,000-Provider Group Shares Treatment Experience

Berge says competing providers collaborate because they want regenerative medicine to advance. He describes a company-created Facebook group where almost 2,000 providers discuss patient situations and compare protocols.

Berge says competitors in the field often cheer for one another
Providers use the group to ask peers about patient situations
The exchanges focus on protocols and practical experience
The group's maxim is collaboration rather than competition

“it's competitive, but most of us in the space are actually cheering for each other because we want to advance this forward.”
Seth Berge · 25:00

“Collaboration, not competition is one of the things we say in that group.”
Seth Berge · 26:00

#collaboration#provider community#protocols

Q&A· 1

Q&A31:00

IV or Direct Injection? Berge Explains the Difference

Asked where the cells from Joe's procedure would go, Berge distinguishes systemic IV delivery from a direct joint injection. He says the IV circulates through the body, while a direct injection concentrates product in an injured encapsulated joint such as the knee.

Berge characterises IV delivery as systemic
He recommends direct placement for a local soft-tissue injury
Joe received both an IV and a knee injection
Berge says the IV alone would not concentrate enough product in the knee

“If you have a direct injury soft tissue damage um an injury we want to directly put the cells right in that area.”
Seth Berge · 32:30

#iv therapy#joint injection#treatment delivery

Tool· 1

Tool36:00

The Wharton's Jelly Blend Used for Hair Restoration

Berge contrasts platelet-rich plasma with a newer blend used in scalp microneedling. He says the formulation combines Wharton's jelly, stem cells, exosomes, hyaluronic acid, and a copper peptide before being microneedled into the scalp.

Berge calls PRP the older approach and says it has limitations
The described blend includes Wharton's jelly and exosomes
Microneedling opens the scalp before the product is applied
Berge says the intended result is healthier, thicker hair

“PRP is the old way. PRP has limitations.”
Seth Berge · 36:00

“We blend it all together and then use a micro needle”
Seth Berge · 36:30

#hair restoration#microneedling#whartons jelly

Takeaway· 3

Takeaway22:30

Why Independent Practices Adopt New Therapies First

Berge says the doctors his company works with are usually in private practice because large hospitals involve more bureaucracy and decision-makers. He describes one independent pain clinic that contacted him after repeated patient requests for cellular therapies.

Independent practices share a common ability to make their own decisions
Hospital adoption is slowed by boards and institutional bureaucracy
Repeated patient demand prompted one pain clinic to investigate the service

“the common denominator for the doctors we work with is they're all going to be they're almost all going to be independent.”
Seth Berge · 22:30

“they've had so many patients come to them asking, "Hey, do you guys do stem cells? Do you guys do, you know, these cellular therapies?"”
Seth Berge · 23:00

#private practice#healthcare adoption#patient demand

Takeaway39:30

When Business Replaces Competitive Sport

Berge describes business as his main sport at age 42 and says he plays to win, including a goal of becoming the largest stem-cell distributor. At the same time, he wants the companies to become strong enough that he can step away more and improve his work-life balance.

Berge channels his former-athlete identity into business
He remains focused on growth and wholesale partnerships
He wants a company that depends less on his constant involvement
He acknowledges that stepping away may conflict with his temperament

“now my main sport is is business.”
Seth Berge · 40:00

“personal goal would be to get maybe a little bit better work life balance.”
Seth Berge · 40:30

#work life balance#competitive mindset#business goals

Takeaway41:00

Berge Wants to Become the Accessible Stem-Cell Guide

Berge says conflicting information and perceived cost leave many people unable to act. His stated professional goal is to make regenerative therapy more understandable and accessible beyond the older demographic reached by dinner seminars.

He says many people believe treatment requires an expensive trip overseas
Conflicting local and overseas messages create indecision
Dinner seminars mainly reach people aged roughly 50 to 80
Berge wants to be an accessible source for a broader audience

“what I'm trying to be is is the the accessible stem cell guy for for anybody.”
Seth Berge · 41:30

#patient education#access#personal mission

Frameworks in this episode

Compliant Claims Marketing Rule

Mobile Concierge Delivery Model

One-to-Many Educational Seminar Funnel

Insights & moments

⚡Myth Buster· 1

When Berge Says Overseas Stem-Cell Treatment Is Actually Needed

◆Hot Take· 1